{"entity":{"id":"nct06257680","kind":"trial","name":"A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of ReT01 ACT run by Beijing Xunsheng Biomedical Research Co., Ltd., now recruiting.","summary":"A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors is a phase 1 interventional study registered as NCT06257680 by Beijing Xunsheng Biomedical Research Co., Ltd., with 15 participants planned, started 2024-04-08. Conditions recorded: Advanced Solid Tumor. Interventions recorded: ReT01 ACT.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06257680","url":"https://clinicaltrials.gov/study/NCT06257680"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["ret01"],"companies":["beijing-xunsheng-biomedical"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06257680","phase":"1","setting":"A Single-armed, Open, Phase I Study of ReT01 ACT Injection in the Treatment of Patients With Advanced Solid Tumors","sponsor":"Beijing Xunsheng Biomedical Research Co., Ltd.","enrolled":15,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06257680/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"ret01","kind":"drug","name":"ReT01 ACT","route":"/drugs/ret01/"}],"company":[{"id":"beijing-xunsheng-biomedical","kind":"company","name":"Beijing Xunsheng Biomedical Research","route":"/companies/beijing-xunsheng-biomedical/"}]}}